HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Altimmune (NASDAQ:ALT) and maintained a price target of $12.
August 22, 2024 | 5:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Altimmune, maintaining a $12 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $12 price target by HC Wainwright & Co. suggests continued confidence in Altimmune's potential, likely leading to positive investor sentiment and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100